全文获取类型
收费全文 | 99453篇 |
免费 | 9455篇 |
国内免费 | 3305篇 |
专业分类
耳鼻咽喉 | 306篇 |
儿科学 | 1341篇 |
妇产科学 | 1183篇 |
基础医学 | 6525篇 |
口腔科学 | 1248篇 |
临床医学 | 9564篇 |
内科学 | 15408篇 |
皮肤病学 | 1322篇 |
神经病学 | 2729篇 |
特种医学 | 1087篇 |
外国民族医学 | 15篇 |
外科学 | 3507篇 |
综合类 | 13695篇 |
现状与发展 | 11篇 |
一般理论 | 3篇 |
预防医学 | 8461篇 |
眼科学 | 785篇 |
药学 | 33868篇 |
36篇 | |
中国医学 | 4277篇 |
肿瘤学 | 6842篇 |
出版年
2024年 | 97篇 |
2023年 | 1434篇 |
2022年 | 1941篇 |
2021年 | 3600篇 |
2020年 | 3495篇 |
2019年 | 3466篇 |
2018年 | 3557篇 |
2017年 | 3711篇 |
2016年 | 3791篇 |
2015年 | 3943篇 |
2014年 | 6644篇 |
2013年 | 9976篇 |
2012年 | 6905篇 |
2011年 | 7191篇 |
2010年 | 5680篇 |
2009年 | 5114篇 |
2008年 | 5098篇 |
2007年 | 5094篇 |
2006年 | 4475篇 |
2005年 | 3965篇 |
2004年 | 3308篇 |
2003年 | 2802篇 |
2002年 | 2185篇 |
2001年 | 2032篇 |
2000年 | 1597篇 |
1999年 | 1378篇 |
1998年 | 1101篇 |
1997年 | 1052篇 |
1996年 | 875篇 |
1995年 | 819篇 |
1994年 | 717篇 |
1993年 | 600篇 |
1992年 | 646篇 |
1991年 | 546篇 |
1990年 | 424篇 |
1989年 | 365篇 |
1988年 | 325篇 |
1987年 | 333篇 |
1986年 | 242篇 |
1985年 | 301篇 |
1984年 | 232篇 |
1983年 | 164篇 |
1982年 | 177篇 |
1981年 | 142篇 |
1980年 | 107篇 |
1979年 | 97篇 |
1978年 | 94篇 |
1977年 | 82篇 |
1976年 | 83篇 |
1975年 | 74篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
川崎病(Kawasaki disease,KD)是一种急性自身免疫性系统性血管炎,是发达国家儿童获得性心脏病的主要病因。KD最严重的后果是冠状动脉病变(coronary artery lesions,CALs),与KD的预后相关。临床研究证实静脉注射丙种球蛋白(IVIG)耐药是CALs的独立危险因素。近年来,一系列的预测模型已被开发来评估IVIG耐药的风险。然而,目前基于KD儿童人口学特征、临床表现、实验室检查及遗传特性的IVIG耐药性预测评分系统在不同民族和同一民族不同地区的人群中存在显著差异,尚未建立适用普遍人群的预测模型。 相似文献
22.
23.
多囊卵巢综合征 (polycystic ovary syndrome, PCOS) 是一种在育龄期女性中常见的疾病, 它的主
要临床表现是月经紊乱、 不孕、 痤疮、 多毛等症状, 可能伴随有糖脂代谢异常。 Adropin 是新近发现的一种
分泌性蛋白, 已证实其在调节糖脂代谢、 改善胰岛素抵抗中发挥着作用, 但具体作用机制及其临床意义尚
未完全明确。 文章简要综述 Adropin 蛋白的作用机理及其在多囊卵巢综合征中的研究进展及临床意义。 相似文献
24.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
25.
26.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
27.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
28.
29.
30.
《Drug discovery today》2022,27(1):246-256
Bromodomain-containing protein 4 (BRD4) is emerging as a therapeutic target that acts synergistically with other targets of small-molecule drugs in cancer. Therefore, the discovery of potential new dual-target inhibitors of BRD4 may be a promising strategy for cancer therapy. In this review, we highlight a series of strategies to design therapeutic dual-target inhibitors of BRD4 that focus on the synergistic functions of this protein. Drug combinations that exploit synthetic lethality, protein–protein interactions, functional complementarity, and blocking of resistance mechanisms could ultimately overcome the barriers inherent to the development of BRD4 inhibitors as future cancer drugs. 相似文献